Checkpoint Inhibitor Therapy
Congress of Clinical Rheumatology adapts again, going hybrid for first 2021 meeting
Like so many rheumatology meetings over the last year and a half, the 2021 Congress of Clinical Rheumatology – East has adapted to suit the rolling waves of the pandemic.
Female patients on immune checkpoint inhibitors at risk for dermatologic adverse events
Combination immune checkpoint inhibitor therapy elevated cutaneous irAE risk
Cutaneous immune-related adverse events often precede noncutaneous events
Checkpoint inhibitor response, adverse event rate similar regardless of autoimmune disease
Patients’ response to anti-CTLA-4 or anti-PD-1 checkpoint therapy for advanced melanoma, and their incidence of immune-related adverse events of grade 3 or higher, were similar regardless of preexisting autoimmune disease, according to data.
Accurately attributing toxicity with combination regimens: An emerging practice challenge
The use of immune checkpoint inhibitors in cancer care has expanded exponentially over the last few years.
Patients with checkpoint-induced myositis, overlap syndrome face worse outcomes
Myositis due to immune checkpoint therapy is rare yet severe, with more than half of patients developing overlapping myasthenia gravis and/or myocarditis, leading to extended hospitalizations and respiratory failure, researchers noted.
Checkpoint induced arthritis severely impacts QoL for patients with cancer
Patients with immune checkpoint therapy-induced inflammatory arthritis report significant social, functional and emotional impacts, compared with cancer and other side effects, according to findings published in BMC Rheumatology.
Walking the tightrope: Balancing tumor response, adverse events of checkpoint inhibitors
Time moves in funny ways in medicine. Physicians and researchers can work for decades in obscurity on a cure for a particular disease and make little progress. But once the critical breakthrough comes, 6 months or a year can change everything.
Early intervention needs to be a ‘team sport’ to curb checkpoint inhibitor-related irAEs
Early intervention is critical in managing patients with immune-related adverse events associated with cancer checkpoint inhibitor therapy, according to a presenter at the 2020 Interdisciplinary Autoimmune Summit.